Announced Thu, 25 Jun · 10:08 IST
Concord Biotech clears Kenya and Uganda regulator inspections at Unit-II
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹1289.90
prior close
₹1299.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2+0.0-0.1-1.6-0.5-0.2-0.4-0.6-1.5+3.8-1.9——
Up moveDown movePending
AI summary
Concord Biotech's Unit-II formulation facility successfully completed inspections by Kenya's Pharmacy and Poisons Board (PPB) and Uganda's National Drug Authority (NDA). The inspection took place from June 18 to June 24, 2026. This clears the facility to manufacture and supply formulations to these African markets, strengthening the company's global regulatory and manufacturing footprint.
Likely market impact
Positive: regulatory clearance enables continued and expanded exports to Kenya and Uganda, supporting international growth plans.